CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Colgate-Palmolive tops Q3 adjusted profit estimates

By Reuters News


Overview

  • US oral and personal care maker's Q3 sales rose 4.6% yr/yr, slightly beating analysts' expectations

  • Adjusted EPS beat analyst expectations, rising 7% yr/yr

  • Company raised full yr 2026 gross margin and EPS guidance


Outlook

  • Colgate-Palmolive now sees 2026 net sales up 4% to 5%, narrowing prior range of 2% to 6% growth

  • Company expects 2026 organic sales growth broadly in line with nine-month performance

  • Company raises 2026 Base Business EPS growth outlook to 5% to 7% from single-digit growth


Result Drivers

  • SALES GROWTH - Organic sales rose 3.6%, supported by 1.7% volume growth and 2.0% pricing, while private label pet food sales dipped 0.2%

  • VOLUME IMPROVEMENT - Co reported fourth consecutive quarter of sequential volume growth

  • INCREASED ADVERTISING - Co said it continued to invest behind its brands with another double-digit increase in advertising in Q3


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Beat*

$5.37 bln

$5.33 bln (14 Analysts)

Q3 Adjusted EPS

Beat

$0.97

$0.93 (17 Analysts)

Q3 EPS

$0.94

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the personal products peer group is "hold."

  • Wall Street's median 12-month price target for Colgate-Palmolive Company is $99.50, about 6.8% above its October 29 closing price of $93.16

  • The stock recently traded at 23 times the next 12-month earnings vs. a P/E of 23 three months ago


Reuters Recommended Reads

  • Oct 28 - Unilever tops Q3 sales estimates, raises dividend

  • Oct 30 - Kenvue Q3 sales slightly beat expectations on self care segment growth

  • Oct 28 - Higher prices lift Danone third-quarter sales


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.